Skip to main content
Erschienen in: Rheumatology International 1/2005

01.11.2005 | Original Article

Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis

verfasst von: M. Skoumal, G. Kolarz, G. Haberhauer, W. Woloszczuk, G. Hawa, A. Klingler

Erschienen in: Rheumatology International | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

We examined OPG and soluble RANKL in the serum (sOPG, sRANKL) and synovial fluid (synOPG, synRANKL) in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). OPG and RANKL were measured in 85 patients (44 with RA, 41 patients with OA) in serum and synovial fluid as well. For measuring of OPG and RANKL ELISA tests were used. The results of OPG and RANKL were compared with clinical and radiological scores. We found a negative correlation for OPG and RANKL in synovial fluids: not only for the whole group of patients (P< 0.003, r=−0.32), but also for the subgroups (RA: P<0.04, r=−0.28, OA: P<0.002, r=−0.54). SRANKL and synRANKL were positively correlated in the whole group (P<0.01, r=0.25) and in the OA group (P<0.02, r=0.35); the RA group was showing a trend (P<0.063, r=0.24), however. Serum OPG was lower in RA, synOPG higher in OA. The difference between the two patient groups was only significant for synOPG (P<0.03, r=0.056), but not for sOPG (P<0.09, r=0.19), sRANKL (P<0.43, r=0.85) or synRANKL (P<0.11, r=0.22). The synOPG:synRANKL ratio was significantly correlated with the Larsen score (P<0.004, r=0.38). Synovial OPG is significantly decreased in rheumatoid joints, whereby synovial RANKL is increased. Lower synOPG could reflect a lower protective effect on bone, thus leading to an earlier and more pronounced bone destruction in RA. However, the effect of different mediators for joint destruction in RA and OA seems not to be important to the pathophysiological changes in the joints. The upregulation of serum OPG might be the result of the inflammation; in contrast, an upregulation of RANKL could not be found in the serum of patients with RA and OA.
Literatur
1.
Zurück zum Zitat Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK (1984) Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864–872PubMed Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK (1984) Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864–872PubMed
2.
Zurück zum Zitat Pincus T, Marcum SB, Callahan LF (1992) Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 19:1885–1894PubMed Pincus T, Marcum SB, Callahan LF (1992) Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 19:1885–1894PubMed
3.
Zurück zum Zitat Scott DL, Symmons DPM, Coulton BL, Popert AJ (1987) Long- term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1(8542):1108–1111CrossRefPubMed Scott DL, Symmons DPM, Coulton BL, Popert AJ (1987) Long- term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1(8542):1108–1111CrossRefPubMed
4.
Zurück zum Zitat Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF (1986) The development of disability in rheumatoid arthritis. Arthritis Rheum 29:494–500PubMed Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF (1986) The development of disability in rheumatoid arthritis. Arthritis Rheum 29:494–500PubMed
5.
Zurück zum Zitat Pincus T, Callahan LF (1986) Taking mortality in rheumatoid arthritis seriously—predictive markers, socioeconomic status and comorbidity. J Rheumatol 13:841–845PubMed Pincus T, Callahan LF (1986) Taking mortality in rheumatoid arthritis seriously—predictive markers, socioeconomic status and comorbidity. J Rheumatol 13:841–845PubMed
6.
Zurück zum Zitat Mulherin D, Fitzgerald O, Bresnihan B (1996) Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 35:1263–1268CrossRefPubMed Mulherin D, Fitzgerald O, Bresnihan B (1996) Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 35:1263–1268CrossRefPubMed
7.
Zurück zum Zitat Palmer DG (1995) The anatomy of the rheumatoid lesion. Br Med Bull 51:286–295PubMed Palmer DG (1995) The anatomy of the rheumatoid lesion. Br Med Bull 51:286–295PubMed
8.
Zurück zum Zitat Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed
9.
Zurück zum Zitat Itonaga I, Fujikawa Y, Sabokar A, Murray DW, Athanasou NA (2000) Rheumatoid arthritis synovial macrophage–osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 192:97–104CrossRefPubMed Itonaga I, Fujikawa Y, Sabokar A, Murray DW, Athanasou NA (2000) Rheumatoid arthritis synovial macrophage–osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 192:97–104CrossRefPubMed
10.
Zurück zum Zitat Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527–538CrossRefPubMed Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527–538CrossRefPubMed
11.
Zurück zum Zitat Fuller K, Wong B, Fox S, Choi Y, Chambers TJ (1988) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188: 997–1001CrossRef Fuller K, Wong B, Fox S, Choi Y, Chambers TJ (1988) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188: 997–1001CrossRef
12.
Zurück zum Zitat Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323CrossRefPubMed Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323CrossRefPubMed
13.
Zurück zum Zitat Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS III, Frankel WN, Lee SY, Choi Y (1997)TRANCE is a novel ligand of the tumor necrosis factor receptor family that activated c-jun N-terminal kinase in T-cells. J Biol Chem 272:25190–25194CrossRefPubMed Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS III, Frankel WN, Lee SY, Choi Y (1997)TRANCE is a novel ligand of the tumor necrosis factor receptor family that activated c-jun N-terminal kinase in T-cells. J Biol Chem 272:25190–25194CrossRefPubMed
14.
Zurück zum Zitat Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T-cells regulate bone loss and joint destruction an adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309CrossRefPubMed Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T-cells regulate bone loss and joint destruction an adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309CrossRefPubMed
15.
Zurück zum Zitat Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP (1999) Evidence for a role of a tumor necrosis factor alpha converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dentritic cell survival. J Biol Chem 274:13613–13618CrossRefPubMed Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP (1999) Evidence for a role of a tumor necrosis factor alpha converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dentritic cell survival. J Biol Chem 274:13613–13618CrossRefPubMed
16.
Zurück zum Zitat Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM (2000) The osteoclast sifferentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:41–50CrossRefPubMed Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM (2000) The osteoclast sifferentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:41–50CrossRefPubMed
17.
Zurück zum Zitat Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. P Natl Acad Sci USA 96:3540–3545CrossRef Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. P Natl Acad Sci USA 96:3540–3545CrossRef
18.
Zurück zum Zitat Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176CrossRefPubMed Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176CrossRefPubMed
19.
Zurück zum Zitat Hofbauer LC, Heufelder AC (2001) Role of receptor activator of nuclear factor -κB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243–253CrossRefPubMed Hofbauer LC, Heufelder AC (2001) Role of receptor activator of nuclear factor -κB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243–253CrossRefPubMed
20.
Zurück zum Zitat Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S (2004) Involvement of receptor activator of nuclear factor -κB ligand osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259–269CrossRef Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S (2004) Involvement of receptor activator of nuclear factor -κB ligand osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259–269CrossRef
21.
Zurück zum Zitat Bolon B, Campagnuolo G, Hu Yl, Duryeda D, Feige U (2000) Arthritis patterns in rats with adjuvant-induced arthritis define distinct mechanisms of joint protection for IL-1ra, sTNF RI and OPG. Ann Rheum Dis 59(Suppl 1):355 Bolon B, Campagnuolo G, Hu Yl, Duryeda D, Feige U (2000) Arthritis patterns in rats with adjuvant-induced arthritis define distinct mechanisms of joint protection for IL-1ra, sTNF RI and OPG. Ann Rheum Dis 59(Suppl 1):355
22.
Zurück zum Zitat Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A (2004) Serumosteoprotegerin but not receptor activator of NF-kappa B ligand correlates with the Larsen score in rheumatoid arthritis. Ann Rheum Dis 63:216–217CrossRefPubMed Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A (2004) Serumosteoprotegerin but not receptor activator of NF-kappa B ligand correlates with the Larsen score in rheumatoid arthritis. Ann Rheum Dis 63:216–217CrossRefPubMed
23.
Zurück zum Zitat Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed
24.
Zurück zum Zitat Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P (1968) Clinical studies with an articular index for the assesments of joint tenderness in patients with rheumatoid arthritis. Q J Med 147:393–406 Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P (1968) Clinical studies with an articular index for the assesments of joint tenderness in patients with rheumatoid arthritis. Q J Med 147:393–406
25.
Zurück zum Zitat Smolen JS, Breedveld FC, Eberl G (1995) Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis. Arthritis Rheum 38:38–43 Smolen JS, Breedveld FC, Eberl G (1995) Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis. Arthritis Rheum 38:38–43
26.
Zurück zum Zitat Larsen A, Dale K, Eek M (1976) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18:481–491 Larsen A, Dale K, Eek M (1976) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 18:481–491
27.
Zurück zum Zitat Altmann RD, Hochberg M, Murphy WA, Wolfe FJ, Lequesne M (1995) Atlas of individual radiographic features in osteoarthritis. Osteoarthr Cartilage 3:3–70 Altmann RD, Hochberg M, Murphy WA, Wolfe FJ, Lequesne M (1995) Atlas of individual radiographic features in osteoarthritis. Osteoarthr Cartilage 3:3–70
28.
Zurück zum Zitat Steinbrocker O, Traeger CH, Battermann RC (1949) Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140:659 Steinbrocker O, Traeger CH, Battermann RC (1949) Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140:659
29.
Zurück zum Zitat Kudlacek S, Schneider P, Pietschmann P, Woloszczuk W, Willvonseder R (2001) The effect of age on serum levels of osteoprotegerin. J Bone Miner Res 16 (Suppl 1) Kudlacek S, Schneider P, Pietschmann P, Woloszczuk W, Willvonseder R (2001) The effect of age on serum levels of osteoprotegerin. J Bone Miner Res 16 (Suppl 1)
30.
Zurück zum Zitat Hawa G, Brinskelle-Schmal N, Glatz K, Maitzen S, Woloszczuk W (2003) Immunoassay for Soluble RANKL (Receptor Activator of NF-κB Ligand) in Serum. Clin Lab 49:461-463 Hawa G, Brinskelle-Schmal N, Glatz K, Maitzen S, Woloszczuk W (2003) Immunoassay for Soluble RANKL (Receptor Activator of NF-κB Ligand) in Serum. Clin Lab 49:461-463
31.
Zurück zum Zitat Li J, Sarosi I, Xan X-Q, Morony S, Capparelli C, Tan H-L, Mc Cabe S (1997) RANK is the intrinsinc hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. P Natl Acad Sci USA 97(4):1566–1571CrossRef Li J, Sarosi I, Xan X-Q, Morony S, Capparelli C, Tan H-L, Mc Cabe S (1997) RANK is the intrinsinc hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. P Natl Acad Sci USA 97(4):1566–1571CrossRef
32.
Zurück zum Zitat Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615CrossRefPubMed Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615CrossRefPubMed
33.
Zurück zum Zitat Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMed Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMed
34.
Zurück zum Zitat Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:259–269CrossRefPubMed Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:259–269CrossRefPubMed
35.
Zurück zum Zitat Collin- Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P (2001) Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:20659–20672CrossRefPubMed Collin- Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P (2001) Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:20659–20672CrossRefPubMed
36.
Zurück zum Zitat Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352PubMed Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352PubMed
37.
Zurück zum Zitat Holstead Jones D, Kong Y-Y, Penninger JM (2002) Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61(Suppl II):ii32–ii39PubMed Holstead Jones D, Kong Y-Y, Penninger JM (2002) Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61(Suppl II):ii32–ii39PubMed
38.
Zurück zum Zitat Kolarz G, Schödl CH, Skoumal M, Woloszczuk W, Wottawa A (2003) Osteoprotegerin serum levels in rheumatoid arthritis. J Mineralstoffwechsel 3:10–12 Kolarz G, Schödl CH, Skoumal M, Woloszczuk W, Wottawa A (2003) Osteoprotegerin serum levels in rheumatoid arthritis. J Mineralstoffwechsel 3:10–12
39.
Zurück zum Zitat Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM (2001) Osteoprotegerin and receptor activator of nuclear factor -κB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 40:623–630CrossRefPubMed Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM (2001) Osteoprotegerin and receptor activator of nuclear factor -κB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 40:623–630CrossRefPubMed
40.
Zurück zum Zitat Kong YY, Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. P Natl Acad Sci USA 96: 3540–3545CrossRef Kong YY, Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. P Natl Acad Sci USA 96: 3540–3545CrossRef
41.
Zurück zum Zitat Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M (2001) The osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand system in cartilage. Arthritis Rheum 44:2768–2776CrossRefPubMed Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M (2001) The osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand system in cartilage. Arthritis Rheum 44:2768–2776CrossRefPubMed
42.
Zurück zum Zitat Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, Tak PP, Haynes DR (2002) Receptor activator NF-kappa B ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondylarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61:1047–1054CrossRefPubMed Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, Tak PP, Haynes DR (2002) Receptor activator NF-kappa B ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondylarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61:1047–1054CrossRefPubMed
43.
Zurück zum Zitat Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, Zannetino A, Ahern MJ, Coleman M, Roberts-Thomson PJ, Kraan M, Tak PP, Smith MD (2003) Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondylarthropathies and osteoarthritis and normal controls. Rheumatology 42:123–34CrossRefPubMed Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, Zannetino A, Ahern MJ, Coleman M, Roberts-Thomson PJ, Kraan M, Tak PP, Smith MD (2003) Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondylarthropathies and osteoarthritis and normal controls. Rheumatology 42:123–34CrossRefPubMed
44.
Zurück zum Zitat Schett G, Redlich K, Smolen JS (2003) The role of Osteoprotegerin in arthritis. Arthritis Res Ther 5:239–245CrossRefPubMed Schett G, Redlich K, Smolen JS (2003) The role of Osteoprotegerin in arthritis. Arthritis Res Ther 5:239–245CrossRefPubMed
45.
Zurück zum Zitat Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wieland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W (2002) High levels of Osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46(7):1744–1753CrossRefPubMed Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wieland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W (2002) High levels of Osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46(7):1744–1753CrossRefPubMed
Metadaten
Titel
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis
verfasst von
M. Skoumal
G. Kolarz
G. Haberhauer
W. Woloszczuk
G. Hawa
A. Klingler
Publikationsdatum
01.11.2005
Erschienen in
Rheumatology International / Ausgabe 1/2005
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-004-0579-1

Weitere Artikel der Ausgabe 1/2005

Rheumatology International 1/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.